IP Library Granted Patent US 9,181,212
Granted Patent B2
US 9,181,212 · App. 14/294,384 · Granted Nov 10, 2015

Method of producing beraprost

Inventors: Vijay Sharma (Olney, MD); Hitesh Batra (Herndon, VA); Sudersan Tuladhar (Silver Spring, MD)
Assignee: Lung Biotechnology PBC
C07D307/93C07C259/06C07F7/1844C07F7/1892C07F9/28C07F9/4006
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,181,212
App. No.
14/294,384
Granted
Nov 10, 2015
Kind
B2
Abstract

An improved method is described for making single isomers of synthetic benzoprostacyclin analog compounds, in particular the pharmacologically active 314-d isomer of beraprost. In contrast to the prior art, the method is stereoselective and requires fewer steps than the known methods for making these compounds.

Claims (21)

1. A process for preparing a substantially pure compound of the following formula:

R 2 represents H or a hydroxy protective group,

R 4 represents H or C 1-3 alkyl,

R 5 represents H or C 1-6 alkyl, and

Z represents C 1-12 alkyl-COOR 12 , R 12 is a cation, H, or C 1-12 alkyl, comprising the steps of:

(1) reacting an aldehyde of the formula

with a substantially pure compound of the formula:

wherein Z′ is C 1-12 alkyl-COOR 12′ , R 12′ is a C 1-6 alkyl or a protecting group, R 2a is a hydroxy protecting group, R 4 and R 5 are each defined above to form a compound of the following formula:

and

(2) selectively reducing the carbonyl and deprotecting secondary alcohol to form a substantially pure compound of the following formula:

2. The method of claim 1 , wherein selective reduction of the carbonyl includes an asymmetric catalyst.

3. The method of claim 1 , further comprising deprotecting the ester of protected acid of Z′ to form an acid or salt thereof.

4. The method of claim 3 , wherein R 4 and R 5 are each CH 3 , Z is (CH 2 ) 3 COO R 12 and R 12 is a cation or H.

5. The method of claim 4 , wherein R 12 is a cation and the cation is K + .

6. The method of claim 5 , wherein the resulting substantially pure compound comprises greater than 99% of the isomer represented by the following formula:

7. The method of claim 3 , wherein Z′ is C 1-12 alkyl-COOR 12′ , and R 12′ is a C 1-6 alkyl.

8. The method of claim 1 , wherein R 2a is a silyl protecting group.

9. The method of claim 8 , wherein R 2a is trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl or phenyldimethylsilyl.

10. The method of claim 1 , wherein said selective reducing uses a selective reducing agent selected from the group consisting of (R)-(+)-2-Butyl-CBS-oxazaborolidine and catecholborane, (R)-(+)-2-Methyl-CBS-oxazaborolidine and catecholborane, (+) DIP-chloride, NaBH 4 and 2-(3-Nitrophenyl)-1,3,2-dioxaborolane-4S,5S-dicarboxylic acid (D-TarB-NO 2 ), modified DIBAL reagents, and modified LAH agents.

11. The method of claim 1 , wherein R 2a is a silyl protecting group and wherein said selective reducing uses a selective reducing agent selected from the group consisting of (R)-(+)-2-Butyl-CBS-oxazaborolidine and catecholborane, (R)-(+)-2-Methyl-CBS-oxazaborolidine and catecholborane, (+) DIP-chloride, NaBH 4 and 2-(3-Nitrophenyl)-1,3,2-dioxaborolane-4S,5S-dicarboxylic acid (D-TarB-NO 2 ), modified DIBAL reagents, and modified LAH agents.

12. The method of claim 11 , wherein R 2a is trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl or phenyldimethylsilyl.

Assignments (1)
CHANGE OF NAME Recorded May 5, 2015
From: LUNG BIOTECHNOLOGY INC.
To: LUNG BIOTECHNOLOGY PBC
Reel/Frame 035574/0927 →
Continuity (3)
Division 13524568 · Jun 15, 2012
Provisional Application 61497754 · Jun 16, 2011
Related Publication 20140275573A1 · Sep 18, 2014